Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors.

Low H19 and abundant IGF-II expression may have a role in the development of adrenocortical carcinomas. In the mouse, the H19 promoter area has been found to be methylated when transcription of the H19 gene is silent and unmethylated when it is active. We used PCR-based methylation analysis and bisulfite genomic sequencing to study the cytosine methylation status of the H19 promoter region in 16 normal adrenals and 30 pathological adrenocortical samples. PCR-based analysis showed higher methylation status at three HpaII-cutting CpG sites of the H19 promoter in adrenocortical carcinomas and in a virilizing adenoma than in their adjacent normal adrenal tissues. Bisulfite genomic sequencing revealed a significantly higher mean degree of methylation at each of 12 CpG sites of the H19 promoter in adrenocortical carcinomas than in normal adrenals (P < 0.01 for all sites) or adrenocortical adenomas (P < 0.01, except P < 0.05 for site 12 and P > 0.05 for site 11). The mean methylation degree of the 12 CpG sites was significantly higher in the adrenocortical carcinomas (mean +/- SE, 76 +/- 7%) than in normal adrenals (41 +/- 2%) or adrenocortical adenomas (45 +/- 3%; both P < 0.005). RNA analysis indicated that the adrenocortical carcinomas expressed less H19 but more IGF-II RNAs than normal adrenal tissues did. The mean methylation degree of the 12 H19 promoter CpG sites correlated negatively with H19 RNA levels (r = -0.550; P < 0.01), but positively with IGF-II mRNA levels (r = 0.805; P < 0.001). In the adrenocortical carcinoma cell line NCI-H295R, abundant IGF-II, but minimal H19, RNA expression was detected by Northern blotting. Treatment with a cytosine methylation inhibitor, 5-aza-2'-deoxycytidine, increased H19 RNA expression, whereas it decreased IGF-II mRNA accumulation dose- and time-dependently (both P < 0.005) and reduced cell proliferation to 10% in 7 d. Our results suggest that altered DNA methylation of the H19 promoter is involved in the abnormal expression of both H19 and IGF-II genes in human adrenocortical carcinomas.

[1]  W. Reik,et al.  An upstream repressor element plays a role in Igf2 imprinting , 2001, The EMBO journal.

[2]  A. Feinberg,et al.  Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. , 2001, Cancer research.

[3]  A. Wolffe,et al.  Transcriptional control: Imprinting insulation , 2000, Current Biology.

[4]  P. Lichter,et al.  Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high‐level amplifications , 2000, Genes, chromosomes & cancer.

[5]  Shirley M. Tilghman,et al.  CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus , 2000, Nature.

[6]  G. Felsenfeld,et al.  Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene , 2000, Nature.

[7]  M. Srivastava,et al.  H19 and Igf2 monoallelic expression is regulated in two distinct ways by a shared cis acting regulatory region upstream of H19. , 2000, Genes & development.

[8]  C. Deal,et al.  Pediatric adrenocortical tumors: molecular events leading to insulin-like growth factor II gene overexpression. , 2000, The Journal of clinical endocrinology and metabolism.

[9]  R. Momparler,et al.  DNA methylation and cancer , 2000, Journal of cellular physiology.

[10]  A. Amsterdam,et al.  Proviral insertions in the zebrafish hagoromo gene, encoding an F-box/WD40-repeat protein, cause stripe pattern anomalies , 2000, Current Biology.

[11]  K D Robertson,et al.  DNA methylation: past, present and future directions. , 2000, Carcinogenesis.

[12]  A. Hoffman,et al.  Symmetric and asymmetric DNA methylation in the human IGF2-H19 imprinted region. , 2000, Genomics.

[13]  Francisco Antequera,et al.  CpG islands as genomic footprints of promoters that are associated with replication origins , 1999, Current Biology.

[14]  C. Gicquel,et al.  Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. , 1999, Journal of molecular endocrinology.

[15]  B. Tycko,et al.  Multipoint analysis of human chromosome 11p15/mouse distal chromosome 7: inclusion of H19/IGF2 in the minimal WT2 region, gene specificity of H19 silencing in Wilms' tumorigenesis and methylation hyper-dependence of H19 imprinting. , 1999, Human molecular genetics.

[16]  A. Feinberg.  Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. , 1999, Cancer research.

[17]  S. Tilghman,et al.  Igf2 imprinting does not require its own DNA methylation or H19 RNA. , 1998, Genes & development.

[18]  O. Haas,et al.  Promoter‐specific methylation and expression alterations of igf2 and h19 are involved in human hepatoblastoma , 1998, International journal of cancer.

[19]  R. Ohlsson,et al.  Inactivation of H19, an imprinted and putative tumor repressor gene, is a preneoplastic event during Wilms' tumorigenesis. , 1997, Cancer research.

[20]  X. Bertagna,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Structural and Functional Abnormalities at 11p15 Are Associated with the Malignant Phenotype in Sporadic Adrenocortical Tumors: Study on a Series , 2022 .

[21]  C Kress,et al.  Deletion of the H19 transcription unit reveals the existence of a putative imprinting control element. , 1997, Genes & development.

[22]  P. Heikkilä,et al.  Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. , 1997, The Journal of clinical endocrinology and metabolism.

[23]  A. Reeve,et al.  Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Chrousos,et al.  Extensive personal experience: adrenocortical tumors. , 1997, The Journal of clinical endocrinology and metabolism.

[25]  P. Heikkilä,et al.  Expression patterns of the c-myc gene in adrenocortical tumors and pheochromocytomas. , 1997, The Journal of endocrinology.

[26]  C. Stewart,et al.  Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. , 1996, Physiological reviews.

[27]  S. Tilghman,et al.  Disruption of imprinting caused by deletion of the H19 gene region in mice , 1995, Nature.

[28]  P. Heikkilä,et al.  H19 and insulin-like growth factor-II gene expression in adrenal tumors and cultured adrenal cells. , 1995, The Journal of clinical endocrinology and metabolism.

[29]  X. Bertagna,et al.  Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. , 1994, The Journal of clinical endocrinology and metabolism.

[30]  A. Hochberg,et al.  Parallel regulation of parentally imprinted H19 and insulin-like growth factor-II genes in cultured human fetal adrenal cells. , 1994, Endocrinology.

[31]  X. Bertagna,et al.  Clonal analysis of human adrenocortical carcinomas and secreting adenomas , 1994, Clinical endocrinology.

[32]  T. Ekström,et al.  Overlapping patterns of IGF2 and H19 expression during human development: biallelic IGF2 expression correlates with a lack of H19 expression. , 1994, Development.

[33]  Rudolf Jaenisch,et al.  Role for DNA methylation in genomic imprinting , 1993, Nature.

[34]  Benjamin Tycko,et al.  Tumour-suppressor activity of H19 RNA , 1993, Nature.

[35]  V. Ilvesmäki,et al.  Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. , 1993, The Journal of clinical endocrinology and metabolism.

[36]  K. Tadokoro,et al.  Polymerase chain reaction (PCR) for detection of ApaI polymorphism at the insulin like growth factor II gene (IGF2). , 1991, Nucleic acids research.

[37]  S. Steinberg,et al.  Insulin-like growth factor II-mediated proliferation of human neuroblastoma. , 1991, The Journal of clinical investigation.

[38]  T. Triche,et al.  Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. , 1990, Cancer research.

[39]  V. Chapman,et al.  Use of a HpaII-polymerase chain reaction assay to study DNA methylation in the Pgk-1 CpG island of mouse embryos at the time of X-chromosome inactivation , 1990, Molecular and cellular biology.

[40]  E. Dees,et al.  The product of the H19 gene may function as an RNA , 1990, Molecular and cellular biology.

[41]  W L Miller,et al.  Hormonal regulation of P450scc (20,22-desmolase) and P450c17 (17 alpha-hydroxylase/17,20-lyase) in cultured human granulosa cells. , 1986, The Journal of clinical endocrinology and metabolism.

[42]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.

[43]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[44]  A. Feinberg.  DNA methylation, genomic imprinting and cancer. , 2000, Current topics in microbiology and immunology.

[45]  M. Brennan,et al.  Adrenocortical carcinoma , 1999, World Journal of Urology.

[46]  A. Feinberg,et al.  Reversal of Loss of Imprinting in Tumor Cells by 5-Aza-2 Updated Version , 2006 .

[47]  J. Wahlfors,et al.  Automated fluorescent genomic sequencing as applied to the methylation analysis of the human ornithine decarboxylase gene. , 1994, DNA sequence : the journal of DNA sequencing and mapping.

[48]  A. Feinberg,et al.  Erratum: Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour , 1994, Nature Genetics.

[49]  R. Voutilainen,et al.  Developmental and hormonal regulation of mRNAs for insulin-like growth factor II and steroidogenic enzymes in human fetal adrenals and gonads. , 1988, DNA.

[50]  T. Ekström,et al.  Overlapping patterns of IGF 2 and H 19 expression during human development : biallelic IGF 2 expression correlates with a lack of H 19 expression , 2022 .